View Older Stories View More Recent Stories
-
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Supp
-
Citius Pharmaceuticals, Inc. to Present at Upcoming March 2022 Conferences
-
Citius Pharmaceuticals (CTXR) Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido
-
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
-
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update
-
Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences
-
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update
-
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma
-
Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls
-
Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients
-
Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)
-
Citius Pharmaceuticals to Present at Upcoming October Investor Conferences
-
Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021
-
Citius Pharmaceuticals (CTXR) PT Raised to $10 at Dawson James
-
Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
-
Citius Pharmaceuticals (CTXR) Acquires Dr. Reddy's (RDY) Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indicatio
-
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
-
Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update
-
Citius Pharmaceuticals (CTXR) Provides First Half 2021 Business Update, Highlights Upcoming Milestones
-
Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones
-
Citius Pharmaceuticals (CTXR) 30-day option implied volatility at 162
-
Citius Pharmaceuticals (CTXR) Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned
-
Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned
-
Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS
-
Citius Pharmaceuticals (CTXR) Achieves Next Interim Analysis Milestone in its Mino-Lok Phase 3 Trial
-
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
-
Citius Pharmaceuticals to be Added to Russell 2000® Index
-
Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting
-
Citius Pharmaceuticals (CTXR) to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy
-
Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy
-
Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations
-
Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update
-
Citius Pharmaceuticals to Participate in Fireside Chat at the Gabelli Funds Virtual Microcap Symposium on Tuesday, May 18
-
Citius Pharmaceuticals to Present Mino-Lok® and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13
-
Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar
-
Citius Pharmaceuticals CEO Myron Holubiak Featured in Benzinga Interview
-
Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25
-
Citius Pharmaceuticals to Feature Product Candidates Including Stem-Cell Therapy for COVID-19-Related Acute Respiratory Conditions at H.C. Wainwright Global Life Sciences Conference March 9-10
-
Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Citius Pharmaceuticals (CTXR) PT Raised to $8 at Dawson James, Following Strategic Business Update
-
Citius Pharmaceuticals (CTXR) Prices 50.83M Share Registered Direct Offering at $1.505/Sh
-
Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
-
Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021
-
Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies at the Virtual Investor Conferences Small and Microcap Showcase on February 4
-
Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-Market
-
Citius Pharmaceuticals (CTXR) Announces $20.0 Million Private Placement of Common Stock, Warrants
-
Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market
-
Citius Pharmaceuticals to Present Update on Proprietary Product Candidates at Two Virtual Conferences in January
-
Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19
-
Citius Pharmaceuticals (CTXR) Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap
